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ABSTRACT
Background Clinically assisted hydration 
(CAH) can be provided in the last days of life as 
drinking declines. The impact of this practice on 
quality of life or survival in the last days of life 
is unclear. Practice varies worldwide concerning 
this emotive issue.
Method Systematic literature review and 
narrative synthesis of studies evaluating the 
impact of, or attitudes toward, CAH in the last 
days of life. Databases were searched up to 
December 2019. Studies were included if the 
majority of participants were in the last 7 days of 
life, and were evaluated using Gough’s 'Weight 
of Evidence' framework. Review protocol 
registered with PROSPERO, registration number 
CRD42019125837.
Results Fifteen studies were included in the 
synthesis. None were judged to be both of high 
quality and relevance. No evidence was found 
that the provision of CAH has an impact on 
symptoms or survival. Patient and family carer 
attitudes toward assisted hydration were diverse.
Conclusion There is currently insufficient 
evidence to draw firm conclusions on the 
impact of CAH in the last days of life. Future 
research needs to focus on patients specifically 
in the last days of life, include those with non- 
malignant diagnoses, and evaluate best ways 
to communicate effectively about this complex 
topic with patients and their families.
INTRODUCTION
Expected deaths tend to be character-
ised by a preceding period of reduced 
consciousness alongside reduction or 
cessation of oral intake.1–3 When drinking 
diminishes, clinically assisted hydration 
(CAH) can be commenced, involving 
medical administration of fluid via an 
intravenous or subcutaneous route.1 
However, questions about the value of 
CAH in the last days of life are conten-
tious, emotive and currently unanswered: 
practice varies considerably between indi-
vidual clinicians, settings and countries.
Many patients, family carers, health-
care professionals (HCPs) and members 
of the public have expressed the view 
that CAH should be given routinely near 
the end of life. A review of the Liverpool 
Care Pathway in the UK found that rela-
tives were concerned that withholding 
CAH had led to dehydration that accel-
erated the dying process.4 The belief 
that dehydration is distressing for dying 
patients is associated with high levels of 
emotional distress for bereaved relatives.5 
HCPs also report concern at the prospect 
of withholding CAH,6 fearing the poten-
tial for dehydration to worsen symptoms 
including delirium, fatigue and thirst.7
Conversely, routine provision of CAH in 
the last days of life is often not supported 
by HCPs experienced in providing end- 
of- life care. CAH can be considered as 
hindering a ‘natural’ death, with hydra-
tion viewed as having the potential to 
increase nausea, dyspnoea, cough, respi-
ratory secretions and the need to urinate.7 
No literature describes similar concerns 
from the public.
These opposing views frequently result 
in differences of opinion between HCPs 
and those in need of their services. Prac-
tice varies markedly between individ-
uals, between healthcare organisations 
and across cultures, with a striking lack 
of consensus. One review noted a broad 
range of 10%–88% of patients with 
cancer receiving CAH in the last week 
of life8; in another, 22%–100% of HCPs 
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life, whereas 1%–75% preferred not to.7 Demon-
strating the impact of cultural norms on practice in this 
field, a Dutch study found 74% of dying hospitalised 
patients received intravenous hydration, compared 
with 2% of dying hospice patients.9 A Delphi study 
defining optimal palliative care in older people with 
dementia found high or very high consensus for 51 out 
of 57 domains but only moderate consensus around the 
statement ‘Hydration… is inappropriate in the dying 
phase’.10 Clinical guidance is also vague; UK guidelines 
state that hydration decisions should be ‘individual-
ised’, but provide little specific information.11
Decisions about CAH can have broader implications, 
including impact on the place of the death. Although 
home is often the preferred place,12 in many coun-
tries parenteral hydration is not available in the home 
setting. The UK’s comprehensive District Nursing 
Manual of Clinical Procedures does not mention home 
hydration.13 A decision to provide CAH, therefore, has 
the potential to prevent a patient from dying at home.
Five systematic reviews have evaluated CAH near 
the end of life, the most recent published in 2014. 
Two reviews investigated attitudes,7 14 one modes of 
CAH delivery,15 and another CAH in palliative care 
patients.16 These revealed a lack of research, with 
limited evidence of benefit. Only one focused on CAH 
at the very end of life; Raijmakers et al’s review of 
CAH in the last week of life of patients with cancer 
found little benefit from this practice.8
Evaluation of CAH in the last days of life is partic-
ularly important, as this is the point when drinking 
tends to diminish rapidly and clinical decision- making 
can be particularly challenging. A systematic review is, 
therefore, needed that focuses on the impact of CAH 
in the last days of life, while allowing broad eligibility 
in relation to study design and participants, in order 
to provide a comprehensive updated appraisal of this 
clinically relevant and emotive topic.
Review aims
To undertake a systematic review of literature evalu-
ating the impact of CAH in the last days of life on 
symptoms and survival, and the attitudes of patients 
and family carers with direct experience of this 
practice.
METHODS
An information specialist (IK) developed a search 
strategy that was adapted for each database searched: 
Medline, CINAHL, PsycINFO all via EBSCO, Embase 
via OVID, Web of Science Core Collection, the 
Cochrane Library, ASSIA via Proquest and AMED via 
NHS HDAS. Box 1 displays the search strategy used 
for Medline. Searches were conducted of the literature 
up to December 2019. Reference searches, citation 
searches and electronic searches of relevant journals 
(Palliative Medicine, Journal of Clinical Oncology, 
Journal of Pain and Symptom Management, BMJ 
Supportive and Palliative Care) were also undertaken.
Abstract screening was conducted independently by 
AK and GC after exclusion of duplicate or irrelevant 
titles, with any disagreements between reviewers being 
resolved by consensus. AK obtained the full text of 
potentially relevant articles. AK and RB assessed their 
eligibility (box 2), extracted data and independently 
graded the articles by Gough’s Weight of Evidence 
(WoE) framework (box 3).17 This framework was 
considered well suited to this review given its emphasis 
on studies’ relevance to the review’s questions, as well 
their quality, along with its flexibility in allowing 
appraisal of studies with a wide range of method-
ology.18 Disagreements were resolved by discussion to 
gain consensus.
AK conducted a narrative synthesis, given the 
utility of this approach when synthesising evidence 
from both qualitative and quantitative studies.19 
Meta- analysis was not possible due to heterogeneous 
methodology and outcome measures. The narrative 
synthesis involved three stages. Initially, a preliminary 
textual synthesis of each study was created, followed 
by inductive thematic analysis, using variable labels as 
themes. Second, to explore relationships within the 
data, AK compared data within and across studies, 
including a process of investigator triangulation that 
considered similarities and differences in methodolog-
ical approaches between studies. Finally, the robustness 
of the synthesis was assessed. Articles of low Gough’s 
WoE rating were included to increase the breadth 
of the review and reveal areas without any research 
evidence, but were given less weight in the synthesis 
and discussion.
Database searches identified 4424 titles after dedu-
plication. After screening 717 abstracts, 15 studies were 
judged to meet inclusion criteria and were included in 
the synthesis (figure 1). No additional eligible studies 
were found from the reference, citation and specific 
journal searches.
The review protocol was registered with PROSPERO 
(registration number CRD42019125837): https://
Box 1 . Medline search strategy
((MH “Terminal Care+“) OR (MH “Terminally |||+“) OR (“end 
of life” or “end- of—Iife” or terminal- stage* or terminal- 
phase* or (terminal* N3 (stage* or phase* or ill*)) OR ((last 
or final) N3 (day* or week* or month*)) OR (“end- stage 
disease*” or “end stage disease*” or “end- stage illness*” 
or “end stage illness”) OR ((“less than” N3 (week* or 
month*)) and (death or die or dying or life or live* or died)))
AND
((fluid* N6 (balanc* or therap* or manag*)) OR (hydrat* 
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www. crd. york. ac. uk/ PROSPERO/ display_ record. php? 
RecordID= 125837.
RESULTS
The fifteen included studies were described in twelve 
peer- reviewed journal papers, one MSc thesis and two 
published abstracts. Using Gough’s framework, eight 
studies were judged to provide ‘medium’ and seven 
‘low’ WoE. One trial was well designed and of high 
quality, but was rated ‘medium’, as it was a feasibility 
study without the design or power to provide defini-
tive outcomes.20
The synthesis included data from 2327 patients and 
131 family caregivers. Dates of publication ranged 
from 1995 to 2019, and studies were conducted in 
several continents: Asia (eight studies), Europe (three), 
North America (two), Oceania (one) and South 
America (one). Three studies reported data collected 
from inpatient participants in palliative care units or 
hospices; six hospital- based data, three from mixed 
locations and three were unclear. The majority of 
studies (13 of 15) recruited only patients with cancer. 
Online supplemental table 1 provides a summary of 
included studies.
Symptoms
Excess respiratory secretions (n=8)
CAH was not associated with severity of respiratory 
secretions in six of eight studies.9 20–25 Two, providing 
medium23 and low25 WoE, respectively, found secre-
tions to be worse in the group that received more 
hydration.
Box 2 . Eligibility criteria
Inclusion criteria
 ► Published papers or abstracts presenting empirical 
research relating to clinically assisted hydration (CAH)
 ► Study population in the last days of life (mean/median 
survival <7 days; if average survival data not reported, 
evidence that the majority of participants were in the last 
7 days of life)
 ► Any geographic location and any setting (hospital, 
hospice, nursing home or home)
 ► Research that assesses one or more of:
 – Symptoms of patients with or without CAH
 – Survival of patients with or without CAH
 – Attitudes towards CAH of patients in last days of life, 
and/or of their relatives (contemporaneous or when 
bereaved)
Exclusion criteria
 ► Case series or case reports
 ► Papers not in English language
 ► Children (aged 17 years or under)
 ► Grey literature
 ► Research with no new empirical data (opinion papers, 
editorials, literature reviews)
 ► Research that assesses:
 – Attitudes towards CAH of healthcare professional, the 
general public or patients not in the last days of life
 – Withdrawal of CAH already being given, for example, 
for patients with prolonged disorders of consciousness
 – The enteral route, for example, fluids via nasogastric 
tube or percutaneous endoscopic gastrostomy
 – Artificial nutrition only
Box 3 . Quality appraisal using Gough’s Weight of 
Evidence (WoE)
For this review’s assessment using WoE framework, papers 
were assigned scores of low, medium or high in the three 
domains A, B and C, as well as the composite fourth domain, 
D.
WoE A: Judged against the internal validity of included 
studies, that is, study rigour, transparency and repeatability 
of method, quality of description of results, accurate analysis, 
and whether conclusions were justified from methods and 
results.
WoE B: Judged on the appropriateness of the study 
design in relation to the review‘s questions. Regarding this 
review’s primary question, study designs were rated more 
highly if they were better suited to demonstrating potential 
causal links between provision or withholding of clinically 
assisted hydration and the development of symptoms.
WoE C: Judged on the relevance of included studies 
regarding the review’s questions. Studies were rated more 
highly if the included participants were in the last week of 
life and if relevant outcome measures were used.
WoE D: The above three judgements are combined to 
form an overall assessment of the extent to which a study 
lends evidence toward answering the review questions.
Review- specific criteria adapted from Gough.17
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Agitation (n=6)
The terms ‘agitation’, ‘delirium’ and ‘restlessness’ were 
frequently used interchangeably. A feasibility trial 
found an unchanged incidence of delirium, although 
its onset was delayed in the group receiving hydra-
tion.20 Four small low WoE studies found no impact 
from CAH.22 23 26 27 An observational study showed 
no association between terminal restlessness and 
volume of fluid intake overall, but did see a significant 
association between higher fluid intake in the final 
25–40 hours, and worse restlessness in the 24 hours 
preceding death.9
Nausea (n=5)
Four studies found no impact of CAH on nausea when 
compared with usual care.20 21 24 28 One small prospec-
tive trial found better relief from nausea at 48 hours in 
the hydration group.26
Breathlessness (n=4)
CAH had no impact on the severity of breathlessness 
in three studies.20 25 28 A retrospective observational 
study of medical records found an association between 
breathlessness severity and administration of higher 
fluid volumes near the end of life21
Oedema/fluid overload (n=4)
Three of four studies found no impact of CAH on 
the incidence or severity of peripheral oedema.22 25 28 
One small observational study noted worse oedema 
in a group receiving higher volumes of hydration.23 
Pleural effusion severity was not influenced by the use 
of CAH,22 23 but two of three studies found CAH to be 
associated with worsening ascites.22–24
Thirst or dry mouth (n=3)
None of the three studies, all published 20 or more 
years ago, demonstrated any impact of CAH on the 
experience of thirst.26 28 29 These studies did not 
draw distinctions between reporting of thirst and dry 
mouth, or comment on use of measures to hydrate the 
oral cavity.
Other symptoms
No impact of CAH was found in relation to pain,20 28 
depression28 or anxiety.21 28
Survival (n=5)
Four of five studies evaluating survival found no differ-
ence in survival between participants receiving or not 
receiving CAH.20 24 26 28 30 The timing of death was 
slightly delayed in the CAH arm of a feasibility trial 
(4.3 vs 2.9 days, p=0.038).20
Patient and carer attitudes (n=5)
Three studies evaluated patient and family caregiver 
attitudes30–32 and two focused on bereaved relatives’ 
views.33 34 The ‘meaning of oral intake’ was recognised 
as important, and of a significance beyond nutritional 
value.33 Although most bereaved relatives regarded 
reduced intake towards the end of life to be normal, 
concerns about both the giving and the withholding 
of assisted hydration were expressed, often simultane-
ously.33 Torres- Vigil et al found that 76% of bereaved 
family caregivers considered that CAH had been bene-
ficial, and that this perception was associated with a 
better ‘initial adjustment to death’.34
DISCUSSION
Fifteen studies have evaluated the impact of, or atti-
tudes towards, CAH on the last days of life. This review 
has found little evidence that CAH has an impact on 
symptoms or survival. Patients and informal carers 
demonstrated varied perspectives that reflect the many 
uncertainties inherent to the provision of CAH at the 
end of life.
Although a small number of studies did report 
changes to symptoms or survival, the heterogeneity 
and low WoE of research focusing specifically on the 
last days of life have precluded definitive conclusions. 
Davies et al made a noteworthy attempt to overcome 
the challenges of undertaking research in this patient 
group, undertaking a naturalistic cluster randomised 
trial involving patients in the last days of life.20 The 
main study findings, of a slight delay in delirium onset 
and timing of death, are intriguing. However, this was 
a feasibility study, not designed to generate definitive 
clinical outcomes.
A number of otherwise highly relevant studies were 
excluded from this review because most participants 
were not in the last week of life, or because insuffi-
cient information had been provided to judge whether 
or not this was the case. In a rigorous trial, Bruera 
et al specifically excluded those in the last 7 days of 
life when randomising home hospice patients with 
advanced cancer to either 1000 or 100 mL of 0.9% 
saline daily; over 7 days there was no impact on symp-
toms or survival.35 Matsuo et al’s naturalistic cohort 
study focused on CAH in patients with advanced cancer 
who had been prescribed steroids, revealing an asso-
ciation between lower received volume of CAH and 
the development of delirium (p=0.034).36 Yamaguchi 
et al found worse agitation (p=0.025) and a higher 
prevalence of agitated delirium (p=0.009) in patients 
with advanced abdominal malignancies receiving less 
CAH.37 Although participants in the latter two studies 
were mostly in the last weeks, rather than last days, 
of life, (and thus excluded from this review), together 
with the findings from the feasibility study included 
in this review,20 there is a suggestion that CAH may 
reduce the incidence or severity of delirium as oral 
intake declines.
Due to the challenges of undertaking research in 
dying patients, few studies have focused on the perspec-
tives of patients and their family carers in the last week 
of life. The qualitative study of the views of bereaved 
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perspectives on CAH at the end of life, with individuals 
sometimes holding complex and conflicting views.33 In 
contrast, a qualitative study of patients with advanced 
cancer in the last weeks, rather than last days, of life, 
found unambiguously positive views of CAH.38 This 
disparity may reflect the differences between views 
expressed in theory, and those resulting from lived 
experience.5 Neither study provided information on 
whether participants had been involved in conversa-
tions with health professionals about potential risks 
and benefits of hydration; Morita et al found that 
patients and relatives tend to adopt the perspectives of 
their clinicians, whether these are for, or against, the 
provision of CAH.39
Strengths and limitations
This study is the first to review literature evaluating 
the provision of CAH to patients with any diagnosis 
in the last week of life, a time when issues of hydra-
tion are particularly relevant and challenging. Its 
comprehensive approach, including a wide range of 
study designs, participant populations and outcome 
measures, supports accurate identification of gaps in 
the literature.
The generally low WoE of the included studies, 
reflecting the ethical and methodological difficulties 
of involving dying patients in research, limited the 
ability to reach firm conclusions that could influence 
clinical practice. Due to the proximity to unconscious-
ness and death, studies tended to incorporate clinician- 
based ratings rather than self- reported measures; 
several involved a retrospective design to overcome 
the difficulty in judging prognosis. Many studies were 
small and underpowered. Outcome measures were 
heterogeneous, and some tested parameters with little 
salience to CAH, such as depression. Most studies only 
included patients with cancer, reducing the generalis-
ability of this review. The search strategy excluded grey 
literature and papers not available in English language, 
and publication bias was not assessed.
Clinical implications
NICE guidance on ‘Care of dying adults in the last 
week of life’ suggests that clinicians should routinely 
raise and discuss the topic of hydration and CAH.11 
Given the lack of evidence to guide decision- making 
and the concerns about both giving and withholding 
CAH, this review reinforces the need for highly skilled 
communication, including explanation of the uncer-
tainties involved. This needs to be carefully individ-
ualised, taking into account both patient and family 
perspectives, as well as the potential impact of CAH 
decisions on the place of care. Current evidence from 
the UK suggests these discussions are not routinely 
held with documented evidence of conversations 
relating to CAH with 9% of dying patients and 30% 
of their relatives.40
In the absence of evidence, pragmatic clinical guid-
ance is likely to be helpful. A study of HCPs’ views 
of guidelines for CAH in palliative care settings 
found that a majority (81%) would welcome guide-
lines that standardise care.41 Current General Medical 
Council guidance avoids discussion of what the bene-
fits and burdens of CAH may be, citing a lack of clear 
evidence.1 This guidance focuses on the process of best 
interests decision making, and emphasises the impor-
tance of frequent reassessment of clinical condition. 
Given that there is insufficient evidence to generate 
definitive criteria for the use of CAH, additional guid-
ance could usefully take a case- based approach that 
encourages clinicians to think through ethical and clin-
ical arguments, while avoiding being prescriptive. In 
2007, the former National Council for Palliative Care 
published case- based guidance on artificial nutrition 
and hydration at the end- of- life care,42 but this is now 
out of date and no longer easily accessible.
The importance of the symbolic significance and 
‘meaning’ of CAH to patients and their families also 
has clinical implications. Guo and Jacelon argue that 
a major component of dignity at the end of life is 
‘feeling human’.43 Some may feel that a drip detracts 
from feeling human by ‘medicalising’ death and 
keeping people in an inpatient setting; others may feel 
it contributes to a feeling of humanity and dignity, by 
symbolising ‘nurturing’ and ‘health’ in the way that 
drinking usually does.38 Clinicians could helpfully 
explore patients’ and relatives’ interpretations of the 
meaning they attach to CAH in order to support the 
process of making decisions about its provision.
Research implications
Definitive studies are urgently needed to determine 
whether CAH has any impact on patients’ survival or 
symptoms. A number of findings from this review can 
helpfully influence the design of future research. This 
review included a feasibility study with an innovative 
methodological approach, involving advance consent 
and cluster randomisation,20 that could be valuable in 
future trials involving dying patients. The high recruit-
ment rate was particularly notable given the difficul-
ties in recruiting and retaining vulnerable participants 
close to death. In addition, it is vital that future 
studies incorporate outcome measures of relevance 
to patients. Despite relatives’ concerns about thirst 
as drinking diminishes towards the end of life,5 32 44 
no studies published in the last 20 years evaluated the 
impact of CAH on thirst.
Given the complexity of communication about 
an emotive topic, yet to be supported by definitive 
evidence, research is needed that evaluates strategies 
to support effective communication about CAH at the 
end of life. Although a recent literature review included 
five papers that touch on the potential for communi-
cation strategies to support families concerned about 
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focused on CAH- related communication. Finally, 
future research needs to involve patients with other 
diagnoses, including dementia and organ failure, given 
the preponderance of studies in cancer populations to 
date.
CONCLUSIONS
This review has found a limited amount of predom-
inantly low- quality research evaluating the impact of 
CAH in the last days of life. There is a pressing need 
for well- designed studies that focus on patients specif-
ically in the last days of life and incorporate outcome 
measures that take patients’ concerns into account. 
In the meantime, clinicians will continue to have to 
answer dying patients’ elemental questions about 
water and thirst, with little evidence on which to base 
the content or manner of their advice.
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